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a  b  s  t  r  a  c  t
Hendra  virus  (HeV)  is  an  emerging  zoonotic  paramyxovirus  within  the  genus  Henipavirus  that  has  caused
severe  morbidity  and  mortality  in  humans  and  horses  in  Australia  since  1994.  HeV  infection  of  host
cells  is mediated  by  the  membrane  bound  attachment  (G)  and fusion  (F)  glycoproteins,  that  are  essential
for  receptor  binding  and  fusion  of  viral  and  cellular  membranes.  The  eukaryotic  unicellular  parasite
Leishmania  tarentolae  has  recently  been  established  as a powerful  tool  to express  recombinant  proteins
with  mammalian-like  glycosylation  patterns,  but only  few  viral  proteins  have  been  expressed  in  this
system  so  far. Here,  we  describe  the puriﬁcation  of a truncated,  Strep-tag  labelled  and  soluble  version
of the  HeV  attachment  protein  (sHeV  G)  expressed  in  stably  transfected  L. tarentolae  cells. After  Strep-eishmania tarentolae
rotein expression
inding assay
tag  puriﬁcation  the  identity  of  sHeV  G was  conﬁrmed  by immunoblotting  and  mass  spectrometry.  The
functional  binding  of  sHeV  G to  the HeV  cell  entry  receptor  ephrin-B2  was  conﬁrmed  in  several  binding
assays.  Generated  polyclonal  rabbit  antiserum  against  sHeV  G  reacted  with  both  HeV  and  Nipah  virus
(NiV)  G  proteins  in immunoﬂuorescence  assay  and efﬁciently  neutralised  NiV  infection,  thus  further
supporting  the  preserved  antigenicity  of  the  puriﬁed  protein.
© 2015  The  Authors.  Published  by  Elsevier  B.V. This  is  an  open  access  article  under  the  CC  BY-NC-ND. Introduction
Hendra virus (HeV) is an emerging virus of the Henipavirus
enus in the Paramyxoviridae family that has ﬁrst been isolated
n Australia in 1994, causing severe respiratory and neurological
iseases in horses and humans with high fatality rates (Barclay
nd Paton, 2000; Selvey et al., 1995). Infections with Nipah virus
NiV), belonging to the same genus, have caused high morbidity
nd mortality rates in pigs and also humans in Southeast Asia since
998 (Chua et al., 2000). In experimental challenge studies, a large
ariety of mammalian species was shown to be susceptible to infec-
ion by HeV (Pallister et al., 2011; Weingartl et al., 2009). This
ide host range may  be due to its usage of the highly conserved
phrin-B2 (EFNB2) as a viral entry receptor (Bonaparte et al., 2005;
∗ Corresponding author.
E-mail address: anne.buschmann@ﬂi.bund.de (A. Balkema-Buschmann).
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166-0934/© 2015 The Authors. Published by Elsevier B.V. This is an open access article 
/).license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Bossart et al., 2008). HeV binding to the host cell is mediated by
the attachment protein G (HeV G), a type II transmembrane glyco-
protein of 604 amino acids that shares structural similarities with
the attachment glycoproteins of other paramyxoviruses (Bowden
et al., 2008; Xu et al., 2008). HeV G elicits a potent neutralising
antibody response in the infected hosts. Due to these facts, HeV G
has become a main target in vaccination, diagnostic and therapeu-
tic strategies to prevent and ﬁght HeV infection (Gao et al., 2015;
Middleton et al., 2014; Mire et al., 2014).
Leishmania tarentolae is a protozoan parasitic organism that nat-
urally infects the lizard Tarentola anularis (Elwasila, 1988). In 2002,
Breitling et al. established a novel eukaryotic protein expression
system that was  based on the stable transfection of L. tarentolae
promastigotes with the respective DNA into the small ribosomal
subunit rRNA gene of the parasite (Breitling et al., 2002). As a
result of their parasitic lifestyle in mammalian hosts, oligosac-
charide structures of the parasitic glycoproteins are often similar
to those of mammalians (Basile and Peticca, 2009; Parodi, 1993).
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.
ologic
G
o
2
p
1
g
s
r
w
2
b
t
t
e
v
b
t
a
t
s
c
c
a
f
e
s
2
2
s
m
a
t
s
G
S
G
K
s
s
t
a
p
2
B
t
p
ﬁ
f
4
s
r
w
1
(
a
w
bK. Fischer et al. / Journal of Vir
lycosylation has a crucial impact on the conformation and thus
n the functionality of a protein (Phan et al., 2009; Soleimani et al.,
007). Therefore, besides the easy handling similar to bacterial
rotein expression and growth rates to high cell densities up to
.4 × 10◦ cells/ml, the mammalian-like N-glycosylation pattern is a
reat advantage of this system. Several mammalian glycoproteins
uch as human laminin-332 and biologically active human eryth-
opoietin (EPO) have been successfully expressed in this system
ith an exceptionally homogenous N-glycosylation (Phan et al.,
009; Breitling et al., 2002). So far, only a few viral proteins have
een expressed in the L. tarentolae system, namely the hepati-
is E capsid protein, the human papillomavirus16 E7 protein and
he inﬂuenza virus hemagglutinin (Baechlein et al., 2013; Salehi
t al., 2012; Pion et al., 2014). Thus, the advantages over con-
entional cell culture expression systems in combination with
eneﬁts in mammalian-like glycosylation patterns could substan-
ially improve the development of glycoprotein-based diagnostic
ssays as well as scientiﬁc analysis of glycoprotein-dependent func-
ions in receptor binding, entry and immune reactions of the host.
Here, we report the expression and puriﬁcation of a truncated
oluble HeV G protein (sHeV G) in stably transfected L. tarentolae
ells. Functionality of sHeV G as a receptor-binding protein was
onﬁrmed in binding and co-precipitation assays. Furthermore,
ntiserum raised in rabbits against sHeV G reacted with G proteins
rom HeV and NiV, and neutralised NiV infection in cell culture
xperiments. In conclusion, the L. tarentolae system proofs to be a
uitable host for the functional expression of viral glycoproteins.
. Materials and methods
.1. Sequence and plasmid construction
For efﬁcient expression in L. tarentolae,  the HeV G coding
equence (GenBank accession no. NC-001906) was codon opti-
ised for L. tarentolae and a truncated G coding sequence (amino
cids 71–604) lacking the transmembrane domain and cytoplasmic
ail together with an N-terminally fused double Strep-tag coding
equence (iba GmbH, Germany; aa sequence: WSHPQFEKGGGSEG-
SGGGSWSHPQFEK) was synthesised (GeneArt AG/Thermo Fisher
cientiﬁc Inc., Germany). This codon-optimised truncated HeV
 sequence was submitted to GenBank under the accession no.
U050076. The product was cloned into the vector pLEXSY-
at2 (Jena Bioscience, Germany) using SalI and NotI restriction
ites to yield pLEXSYHeVG. After ligation, E. coli DH5alpha were
ransformed with the respective construct and cultivated under
mpicillin selection at 33 ◦C for up to 2 days. Resistant clones were
icked and plasmid identities were conﬁrmed by sequencing.
.2. Cultivation, transfection and clonal selection of L. tarentolae
L. tarentolae strain P10 (Jena Bioscience) was  cultivated in
rain–Heart Infusion (BHI) medium according to the manufac-
urer’s instructions. Before transfection, 20 g of the plasmid
LEXSYHeVG were digested with SwaI for linearisation and puri-
ed using the QIAquick Nucleotide Removal kit (Qiagen, Germany)
ollowing the manufacturer’s instructions. At day 2 of cultivation,
.5 ml  of a culture of L. tarentolae in log growth phase (optical den-
ity (OD600) 1.5) were centrifuged at 200 × g for 7 min  at 4 ◦C to
ecover the cells. After resuspension in 350 l of BHI medium, cells
ere mixed with the linearised plasmid DNA and incubated for
0 min  on ice. The mix  was then transferred to a 4.0 mm cuvette
BioRad, Hercules, USA) and electroporated by two pulses (0.3 ms)
t 1500 V. After another incubation period of 10 min  on ice, cells
ere transferred to 10 ml  of fresh BHI medium and further incu-
ated at 26 ◦C.al Methods 228 (2016) 48–54 49
Clonal selection was  started at 48 h after transfection. Cells were
centrifuged at 330 × g for 7 min  at 4 ◦C and resuspended in 10 ml
fresh BHI medium containing the selection marker nourseothricin
(Jena Bioscience) in a ﬁnal concentration of 100 g/ml. Then, 100 l
of this cell suspension were added per well of a 96-well plate
and screened for cell vitality during the following days. Cells were
grown in liquid culture by continuously increasing the culture
volume. Successful transfection and genomic integration was con-
ﬁrmed by PCR with primers F3001 and A1715 (Jena Bioscience).
Glycerol stocks were prepared and stored at −80 ◦C.
2.3. Expression and puriﬁcation of Strep-tagged sHeV G
Cell lysates as well as cell culture supernatant of 5 ml  densely
grown cultures were investigated by immunoblot as described
below for initial screening of protein expression. The total protein
from the supernatant was  precipitated by addition of 50% trichlo-
racetic acid (TCA) to a ﬁnal concentration of 10% followed by two
washes with 80% acetone. For puriﬁcation of Strep-tagged sHeV G
protein from cell lysates, stably transfected L. tarentolae cells were
cultivated in 1 L batches for 3–4 days until an OD600 of 2.0–2.5 was
reached. Then, cells were harvested by centrifugation for 15 min  at
1200 × g and 4 ◦C followed by resuspension in 10 ml  of lysis buffer
(50 mM  Tris–HCl pH 7.4, 150 mM NaCl, 2 mM CaCl2, 0.5% TritionX-
100, 1× protease inhibitor cocktail (Roche, USA) and incubation for
40 min  on ice. Cell extracts were centrifuged for 35 min  (20,817 × g,
4 ◦C). Afterwards, the supernatant was  incubated overnight with
1 ml  (0.5 g/ml) of Strep-Tactin® Sepharose® (iba GmbH) in lysis
buffer at 4 ◦C. Four washing steps with 3 ml  of washing buffer
(50 mM  Tris–HCl pH7.4, 150 mM NaCl, 2 mM CaCl2) were per-
formed by centrifugation and resuspension before the resin was
transferred into a disposable column (Pierce, USA) followed by ﬁve
additional washing steps. Bound proteins were sequentially eluted
with six 0.5 ml  aliquots of elution buffer (100 mM Tris–HCl pH 8.0,
150 mM NaCl, 1 mM EDTA, 2.5 mM  d-Desthiobiotin). Incubation of
the third fraction of elution buffer on the column was  extended to
60 min  at 4 ◦C to increase protein yield.
2.4. Immunoblot analysis, silver staining and glycosidase
treatment
Puriﬁed protein samples were separated on 7% SDS-
polyacrylamide gels (PAGE) under reducing conditions and
transferred to PVDF membranes for immunoblot analysis. After
1 h of blocking in 10% skim milk diluted in PBS/0.05% Tween-20
(PBST), the membrane was  incubated for 1 h with a monoclonal
mouse anti-StrepMAB-Classic (StrepMAB; iba GmbH) at a 1:3000
dilution. After three washing steps with PBST, the secondary anti-
body goat anti-mouse-horseradish peroxidase (HRP; polyclonal,
1:3000; Dianova, Germany) was added for 1 h followed by three
washes. Immunoblot was  developed with SuperSignal West Pico
Chemiluminescent Substrate (Thermo Scientiﬁc, USA). Signals
were visualised using the Quantity One analysis software (BioRad,
Germany). Proteins in the elution fractions were separated by
10% SDS-PAGE (Laemmli, 1970) and visualised by silver staining
(Chevallet et al., 2006). To analyse glycosylation of sHeV G, 2 g
of puriﬁed protein were incubated with 1 unit PNGase F (New
England Biolabs, Germany) for 2 h at 37 ◦C and further analysed by
immunoblot as described above.
2.5. Matrix-assisted laser desorption/ionisation mass
spectrometry (MALDI-TOF/TOF MS)
Peptide mass ﬁngerprint spectra were acquired using standard
procedures for in-gel protein digestion (Shevchenko et al., 2006).
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ore detailed information referring to MS  analysis has been
eposited in the Supplementary data.
.6. Binding of recombinant human EFNB2 to sHeV G
A 96-well plate (Medisorp, Thermo Fisher Scientiﬁc Inc.,
ermany) was coated with 100 l of a dilution of 2 g/ml of sHeV G
n PBS overnight at 4 ◦C. Plates were blocked with 2% BSA in PBST for
 h at 37 ◦C, followed by three washes with PBST. All reagents were
iluted in 0.5% BSA/PBST. Increasing amounts of recombinant solu-
le human ephrin-B2/Fc-Tag (EFNB2/Fc) (Sino Biological Inc., USA)
rom 0.625 ng to 20 ng were added per well. One porcine serum
nd a serum from a HeV infected pig (kindly provided by Hana
eingartl, National Centre for Foreign Animal Disease, Canada)
ere used in a 1:100 dilution as negative and positive controls.
o estimate inﬂuences of unspeciﬁc binding between EFNB2/Fc
nd Leishmania-derived proteins, Strep-tag puriﬁed cell extract of
ntransfected Leishmania cells was coated to control wells. Plates
ere incubated for 1 h at 37 ◦C, followed by three washes with PBST.
rotein G-HRP conjugate (Calbiochem, USA) (1:5000) was added
nd after another 1 h of incubation and three washes, the reaction
as developed with an 2,2′-azino-bis(3-ethylbenzothiazoline-6-
ulphonic acid) (ABTS) substrate (Roche, USA), stopped with 1% SDS
nd absorbance was measured at 405 nm in a Tecan inﬁnite 200Pro
LISA Reader (Tecan Deutschland GmbH, Germany).
For co-precipitation of sHeV G by EFNB2/Fc, 50 l (the equiva-
ent of 1.5 mg)  of Dynabeads Protein G (novex by life technologies,
orway) were incubated under rotation with 4 g of EFNB2/Fc
or 30 min  at room temperature (RT). After washing with 200 l
BS/0.02% Tween-20 (0.02% PBST), 20 g sHeV G diluted in 200 l
.02% PBST were added, followed by another 30 min  of rotating
ncubation at RT. Then, the complex was washed two  times using
00 l of 0.02% PBST, resuspended in 100 l of 0.02% PBST and
ransferred to a clean tube. Elution was carried out using 30 l
f 4× Laemmli buffer (Laemmli, 1970) complemented with 10%
-mercaptoethanol and a ﬁnal heating step at 70 ◦C for 10 min.
amples were run on a 7% SDS-PAGE and transferred to PVDF mem-
rane for Western blot analysis of sHeV G protein as described
bove. In control reactions, a polyclonal rabbit EFNB2 antibody
Sigma–Aldrich, Germany) was used in a dilution of 1:500. As
econdary antibodies, goat -mouse-HRP and goat -rabbit-HRP
ntibodies (Dianova) were used at a 1:3000 dilution.
.7. Cells and transfection
Rabbit Kidney 13 (RK-13), Chinese Hamster Ovary K1 (CHO-K1)
nd Human Embryonic Kidney 293T (HEK293T) cells (Collection of
ell Lines in Veterinary Medicine, Friedrich-Loefﬂer-Institut, Insel
iems, Germany) were cultivated in Minimal Essential Medium
MEM,  Earl’s and Hank’s salts 1:1) supplemented with non-
ssential amino acids and 10% foetal calf serum. Vero 76 cells (ATCC
CRL1587) were cultivated in Dulbecco’s modiﬁed Eagle’s medium
DMEM) with 10% foetal calf serum (FCS), 100 U of penicillin/ml,
.1 mg  of streptomycin/ml, and 4 mM glutamine (Life Technolo-
ies).
Transfection of HEK293T cells was performed using
olyethylenimine (PEI; Sigma–Aldrich) as described previously
Bauer et al., 2014).
.8. Cell adhesion assay
The cell adhesion assay was performed using RK-13 cells,
ndogenously expressing EFNB2 receptors, as well as CHO-K1 cells,
hich lack these receptors. Initially, 96-well plates were coated
ith dilutions of sHeV G ranging from 0.1 to 20 g/ml in PBS at 4 ◦C
vernight and then blocked with 2% BSA in PBS for 1 h at 37 ◦C. Wellsal Methods 228 (2016) 48–54
without sHeV G were only coated with 2% BSA and served as block-
ing control. As positive adhesion control, wells were coated with
poly-l-lysine solution only (Sigma–Aldrich). Cells were detached
with PBS containing 10 mM EDTA, subsequently suspended in
serum-free MEM  and seeded in a density of 1 × 105 cells/ml to
each well. After incubation for 1 h at 37 ◦C, unbound cells were
removed by stringent washing and attached cells were ﬁxed with
3% paraformaldehyde (PFA; in PBS) for 45 min. Following two
washes, cells were stained with 0.5% crystal violet for 30 min. After
extensive washing with distilled water, colour was extracted in
100 l of 0.1 M sodium citrate in 50% ethanol. The absorbance was
measured at 550 nm.
2.9. Generation of polyclonal rabbit antiserum against sHeV G
Antiserum against sHeV G was produced in two  rabbits by three
consecutive immunisations. For each rabbit, the ﬁrst inoculation
contained 100 g of sHeV G in elution buffer mixed in a 1:1 ratio
with complete Freund’s adjuvant. The total volume of 1 ml was
injected subcutaneously at four different sites. The second and third
inoculations were performed after 3 and 6 weeks, by injection of
50 g of sHeV G in incomplete Freund’s adjuvant. Two  weeks after
the third inoculation, serum was  collected and tested for reactivity.
It is referred to as RAb4048.
2.10. Indirect immunoﬂuorescence assay (IFA)
For indirect IFA, transfection of expression plasmids pCAGGS
HeV G (unpublished) and pczCFG5 NiV G (Moll et al., 2004) into
HEK293T cells was  performed as described above. After 20 h, mono-
layer cultures were ﬁxed with 3% PFA and permeabilised with
0.5% Triton-X100 (Sigma–Aldrich) in PBS. Immunodetection of HeV
G and NiV G was  performed using the polyclonal RAb4048 at a
dilution of 1:2000 and 1:1000 respectively and Cy3-conjugated
secondary antibodies (1:1000 in PBS; Dianova). All images were
acquired with a Leica SP5 confocal laser scanning microscope.
Images were processed with the ImageJ software version 1.45 s
(Schneider et al., 2012).
2.11. Virus neutralisation
All NiV infection experiments were performed in the biosafety-
level 4 (BSL-4) containment at the Institute of Virology, Philipps
University of Marburg, Germany.
NiV was propagated and titrated in Vero 76 cells as described
earlier (Weise et al., 2010). To test if the G-speciﬁc antiserum
can neutralise replicative henipaviruses, 180 l of heat-inactivated
RAb4048 serum dilutions (diluted 1:2, 1:20 or 1:2000 in DMEM)
were mixed with 20 l of a NiV suspension containing 2 × 104
infectious units (TCID50). After incubation for 45 min at 37 ◦C,
the serum–virus mixture was added to conﬂuent Vero 76 cells
grown on coverslips (2 × 105 cells). Following virus adsorption for
45 min  at 37 ◦C, cells were extensively washed and then supple-
mented with DMEM containing 2% FCS. After 22 h, cells were ﬁxed
and inactivated with 4% PFA for 48 h. After permeabilisation with
methanol–acetone (1:1), virus-positive syncytia were stained with
a NiV-speciﬁc guinea pig antiserum as described previously (Lamp
et al., 2013).
3. Results
3.1. Cloning and genomic integration of pLEXSYHeVGIt was our aim to express a soluble and Strep-tagged variant
of the HeV G-protein for future application in serological assays.
For this purpose, codon usage of the desired viral sequence was
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Fig. 1. Expression and puriﬁcation of Strep-tagged sHeV G. (A) TCA-precipitated cell culture supernatant (lane 1), L. tarentolae cell lysate (lane 2), Strep-tag-puriﬁed cell
c d by 7% SDS-PAGE and analysed in immunoblot using an StrepMAB  antibody. (B) Elution
f r reducing conditions and visualised by silver staining. (C) Immunoblot analysis of elution
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Fig. 2. Binding of recombinant soluble EFNB2/Fc-tag to sHeV G. Binding assay was
performed as described in Section 2. Brieﬂy, recombinant sHeV G was coated to
the  96-well plate. Soluble EFNB2/Fc in the indicated amounts was  applied. Anti-
HeV pig antiserum (HeV pig serum) and anti-HeV IgG negative pig serum (mockulture supernatant (lane 3) and Strep-tag-puriﬁed cell lysate (lane 4) were separate
ractions E1–E6 of Strep-tag puriﬁed sHeV G were separated by 10% SDS-PAGE unde
raction  E3 with (+) and without (−) PNGase F treatment using StrepMAB.
ptimised for L. tarentolae,  a Strep-tag was added N-terminally and
he sequence was fused in-frame to a secretory signal peptide (SP)
f Leishmania mexicana secreted acid phosphatase (LMSAP), lead-
ng to the construct pLEXSYHeVG (Suppl. Fig. 1). Sequencing of the
btained clones revealed 100% sequence identity with the expected
onstruct. Sequence-veriﬁed plasmids were subsequently electro-
orated into the expression host L. tarentolae.  The correct genomic
ntegration of the expression cassette into the small subunit rRNA
ene (ssu locus) of L. tarentolae was conﬁrmed by analytical PCR.
orty recombinant clones were identiﬁed, from which ﬁve were
andomly selected for expression analysis.
.2. Protein expression, puriﬁcation and immunoblot analysis
Expression and secretion of sHeV G was  analysed by
mmunoblot analysis of TCA-precipitated cell culture supernatant
nd cell lysates (Fig. 1, A, lanes 1 and 2). Although Strep-tagged
HeV G was readily expressed in L. tarentolae,  it was  not efﬁciently
ecreted into the growth medium. Puriﬁcation of the recombi-
ant protein by Strep-tag afﬁnity chromatography from the cell
upernatant and from cell lysates conﬁrmed this ﬁnding (Fig. 1A,
anes 3 and 4). Due to the intracellular accumulation of the pro-
ein, cell lysates were subsequently used for further puriﬁcation
f the recombinant protein. After puriﬁcation of sHeVG, the elec-
rophoretic analysis of six elution fractions demonstrated the
nrichment of the approximately 70 kDa comprising sHeV G pro-
ein (Fig. 1B). Up to 500 g of recombinant sHeV G were puriﬁed
rom 1 L of densely grown static Leishmania culture after four
ays of cultivation. The glycosylation of the recombinant protein
as tested by incubation with PNGase F, resulting in a mass shift
f approximately 7–8 kDa of the sHeV G in comparison to the
ntreated control in the immunoblot analysis (Fig. 1C). Further-
ore, the puriﬁed protein was analysed by MS.  For this purpose,
t was digested with trypsin, the resulting peptides were subjected
o a peptide mass ﬁngerprint analysis and 40 masses of the ﬁnger-
rint spectrum were subjected to tandem MS  analysis. The peptide
pectra covered 71% of the sequence and 44.4% of the sequence
ould be conﬁrmed by tandem MS  (Suppl. Fig. 2A). Notably, the N-
nd C-termini were as well identiﬁed as the Strep-tag (AA 1–28).
oreover, the N-terminal tryptic fragment (WSHPQFEK) could
e unambiguously identiﬁed by tandem MS  of mass 1058.505 Da
Suppl. Fig. 2B) indicating that the N-terminus had been processed
s expected. Tryptic peptides representing the SP of LMSAP were
ot detected..3. Binding of sHeV G to soluble and cellular EFNB2
To assess whether the conformation of the puriﬁed sHeV G
ndeed allows binding to the HeV entry receptor, the efﬁciencyserum) served as controls. As a control for unspeciﬁc binding, 20 ng of EFNB2/Fc
was  applied to wells coated with Strep-tag-puriﬁed cell lysate of non-expressing L.
tarentolae cells. OD was measured at 405 nm.
of sHeV G binding to EFNB2 was  tested. After coating of an ELISA
plate with sHeV G at a concentration of 2 g sHeVG/ml, recombi-
nant EFNB2/Fc was  added in increasing amounts and binding of the
receptor was visualised by ﬁnal OD measurement. sHeV G indeed
captured the EFNB2/Fc protein (Fig. 2), showing a dose-dependent
interaction of EFNB2/Fc with the recombinant protein sHeV G
expressed in L. tarentolae.  The strong binding of the recombinant
receptor to the L. tarentolae expressed sHeV G further indicates a
conformation of the puriﬁed protein that is not in conﬂict with
receptor binding.
To identify speciﬁc interaction between sHeV G and EFNB2,
co-precipitation experiments were performed. As shown in Fig. 3,
sHeV G was  efﬁciently precipitated by recombinant EFNB2/Fc. Incu-
bation of EFNB2/Fc with a L. tarentolae extract of cells lacking the
HeV G gene did not result in precipitated proteins. Since sHeV G
did not bind to the protein G dynabeads, we conclude that the
Leishmania-expressed sHeV G interacts speciﬁcally with the HeV
cell entry receptor EFNB2.
Finally, to assess if sHeV G is able to bind to the cellular HeV
receptor EFNB2 in its native environment, a receptor-binding study
was performed with EFNB2 positive and negative cell lines. RK-
13 cells have been reported to be a very sensitive cell line to
HeV infection (Halpin et al., 2000) and therefore were chosen as
receptor-positive cells. In contrast, CHO-K1 cells, which are refrac-
tory to HeV infection, as they do not express EFNB2 (Negrete et al.,
2005), were selected as negative control. As shown in Fig. 4, recom-
binant sHeV G bound to RK-13 cells in a dose-dependent and
52 K. Fischer et al. / Journal of Virologic
Fig. 3. Co-precipitation of sHeV G by EFNB2/Fc. To conﬁrm the interaction of EFNB2
with sHeV G, a co-precipitation was conducted. Western Blot was  performed detec-
ting either (A) sHeV G via StrepMAB-Classic antibodies or (B) EFNB2/Fc using EFNB2
antibody. EFNB2/Fc was  bound to protein G dynabeads and incubated with sHeV G
(lane 1). To test for unspeciﬁc binding of sHeV G to the dynabeads, sHeV G was
incubated with dynabeads only (lane 2). L. tarentolae cell lysate of untransfected
Leishmania cells was  incubated with EFNB2/fc bound to dynabeads and served as
negative control (lane 3). Controls for recombinant sHeV G and EFNB2/Fc are shown
in  the last two  lanes.
Fig. 4. Cell adhesion assay activity of sHeV G. 96-well plates were coated with increasin
cells  and (B) of CHO cells were added and incubated for 1 h at 37 ◦C. After washing and ﬁxa
of  crystal violet staining. Data are expressed as the means of triplicate results.
Fig. 5. Immunoﬂuorescence assay (IFA) in transfected HEK293T cells. Mock transfected or 
G  rabbit antiserum (RAb4048) and a goat anti-rabbit Cy3-conjugate. Nuclei were counter
scanning microscope. Magniﬁcation, 630×.al Methods 228 (2016) 48–54
saturable manner, thus conﬁrming a speciﬁc interaction between
the cellular EFNB2 receptor and the recombinant protein. In con-
trast, CHO-K1 cells did not bind to the recombinant protein.
Altogether, these results argue for a correct folding of the recombi-
nant protein expressed in L. tarentolae cells.
3.4. Generation of polyclonal rabbit antiserum against sHeV G
To investigate the immunogenic potential of puriﬁed sHeV G it
was used to immunise rabbits. After three immunisations with 100
and 50 g of sHeVG, the serum RAb4048 was  obtained and tested
in HeV G or NiV G expressing HEK293T cells. Serum dilutions of
1:2000 (HeV G) and 1:1000 (NiV G) resulted in convincing visual-
isation of both proteins, whereas no signals were obtained in cells
transfected with empty vector as a negative control (Fig. 5). These
data show that antibodies induced by sHeV G also bind to native
HeV G proteins. Moreover, a strong cross-reactivity for both, HeV
G and NiV G, was  observed.
In agreement with the observed cross-reactivity, a dilution of
1:20 showed almost complete neutralisation of NiV-induced virus
foci (Fig. 6).
4. DiscussionWe  here describe the expression, puriﬁcation and characterisa-
tion of a recombinant truncated HeV G protein (sHeV G) expressed
in L. tarentolae. With the yield of up to 0.5 mg sHeVG per litre
g concentrations of puriﬁed sHeV G. Subsequently, 1 × 105 cells/well of (A) RK-13
tion of attached cells, relative numbers of attached cells were assessed by intensity
HeV G- or NiV G-expressing HEK293T cells were ﬁxed and stained with an anti-sHeV
stained with Hoechst 33342. Images were recorded with a Leica SP5 confocal laser
K. Fischer et al. / Journal of Virological Methods 228 (2016) 48–54 53
Fig. 6. Virus neutralisation. Vero 76 cells were inoculated with NiV at a multiplicity of infection (m.o.i.) of 0.1. Except for the control infection (w/o antiserum), virus inoculum
was  pre-incubated for 45 min  at 37 ◦C with the indicated dilutions of the RAb4048 antiserum. Virus–serum mixtures were added to the cells and proceeded as described
in  Section 2. To visualise NiV-induced foci, the samples were stained with NiV-speciﬁc polyclonal guinea pig antiserum and AlexaFluor-568 labelled secondary antibodies.
Nuclei  were counterstained with DAPI. Images were taken with a Zeiss Axiophot microscope. Magniﬁcation, 200×.
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teishmania cell culture, the recombinant sHeV G protein was
fﬁciently puriﬁed from cell extracts, indicating that the applied
ystem is indeed suitable for the production of sHeV G pro-
ein, even though the initially intended secretion of the protein
as not detectable. Most importantly, we here show that (i) the
eishmania-expressed sHeV G protein is able to bind to ephrinB2
s a cellular receptor molecule which is utilised by Hendra virus,
ii) it induces antibody production against Hendra virus G protein
hat are also cross-reactive against the related NiV G protein and
iii) NiV is neutralised by sHeV G derived rabbit sera.
The sHeV G protein was expressed as a cytoplasmic tail and
ransmembrane domain deleted HeV G protein in which the
uthentic HeV signal peptide was replaced by a secretory signal
eptide (SP) of L. mexicana secreted acid phosphatase (LMSAP)
or efﬁcient targeting to the ER. Therefore, it was  surprising that
o secretion of the soluble protein into the cell culture super-
atant was detectable. As mass spectrometry conﬁrmed cleavage
f the SP by the detection of the expected N-terminal peptide, it is
ost likely that the sHeV G protein was correctly synthesised and
rocessed in the ER and that the observed retention is correlated to
ownstream secretory pathway steps. It has been shown that mod-
ﬁcations in the LMSAP signal peptide sequence may  increase the
ecretion of recombinant antibody fragments (Klatt and Konthur,
012). However, since we assume that the majority of sHeV G pro-
ein is correctly cleaved by a signal peptidase, it is rather unlikely
hat in case of sHeV G protein modiﬁcations in the LMSAP signal
eptide sequence could increase the secretion efﬁciency. More-
ver, production of inﬂuenza virus hemagglutinin (HA) protein was
mpaired by fusion to the LMSAP signal peptide sequence, while
sing the authentic inﬂuenza virus SP sequence consistently lead
o efﬁcient HA production (Pion et al., 2014), indicating that the
MSAP signal peptide can also be inhibitory to glycoprotein secre-
ion. Whether insertion of the authentic virus SP into the sHeV G
xpression constructs increases the sHeV G secretion in a similar
ay, or whether other factors are involved in G protein retention
emains to be investigated. As earlier studies have shown that pro-
eins can be expressed and puriﬁed in the L. tarentolae expression
ystem in a range of 0.1–5 mg/L cell culture (Baechlein et al., 2013;
asile and Peticca, 2009; Klatt and Konthur, 2012), our yield of
.5 mg  of sHeV G protein/litre cell culture proved that the puriﬁ-
ation of intracellular sHeV G from cell lysates was  an appropriate
lternative to the puriﬁcation of secreted protein.
The use of L. tarentolae expression system has considerable
dvantages as compared to conventional protein expression sys-
ems. Firstly, due to a doubling time of 4–5 h and cultivation in acomplex medium without supplementation of CO2, the handling
of L. tarentolae is rather simple (Fritsche et al., 2007). Secondly, the
N-glycosylation pattern in L. tarentolae is exceptionally homoge-
nous with a high eukaryote-like bi-antennary oligosaccharide and
Man3GlcNAc2 core structure lacking higher branched N-glycans
(Breitling et al., 2002). It was  shown that the complexity of glyco-
sylation of recombinant HeV G proteins expressed in two different
systems affected the afﬁnity between the host cell receptor EFNB2
and soluble forms of recombinant HeV G (Colgrave et al., 2012).
In comparison to baculovirus expressed HeV G from insect cells,
HeV G produced in mammalian cells showed a more complex gly-
cosylation pattern and bound more efﬁciently to the HeV receptor
EFNB2. In contrast to this, it was recently shown that mutations in
HeV G leading to the lack of glycosylation sites may  even trigger
a stronger binding of the resulting protein to the EFNB2 receptor
(Bradel-Tretheway et al., 2015). Our data show that L. tarentolae-
expressed sHeV G efﬁciently bound to recombinant EFNB2 and
EFNB2 expressing cells indicating that the glycosylation pattern of
the Leishmania-expressed protein is not detrimental to receptor
binding.
Most importantly, functional integrity of sHeV G in terms of
receptor binding strongly indicated a preserved HeV G-like pro-
tein conformation, which is crucial for the use for serological assays
and the induction of neutralising antibodies against the virus. Sim-
ilar to truncated G protein expressed in mammalian cells (Bossart
et al., 2005), the polyclonal antiserum raised against Leishmania-
expressed G was not only reactive against both the HeV and NiV G
proteins in immunostaining but also blocked NiV infection. Simi-
lar cross-reactivity was reported for sera from experimentally HeV
infected pigs that neutralised NiV in a plaque reduction neutralisa-
tion test (Li et al., 2010).
We  therefore conclude that the here described procedure of HeV
G expression and puriﬁcation is a promising approach for the pro-
duction of antigen for the establishment of diagnostic assays and
antiviral reagents.
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